In addition, because of the complexity of breast cancer and to get a broader perspective in multiple breast cancer cell lines, we characterised the proteomic response to neratinib treatment in two other overexpressing HER2 cell lines (HCC1954 and SKBR3). This evidence concerns the gene ERBB2 and breast carcinoma.